Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT ...
Sam Altman, the CEO of OpenAI, has announced a shift in his previously critical perspective on President Donald Trump.
Since then, Musk hasn’t hidden his anger with Altman and OpenAI. He’s currently suing the company over its decision to become ...
Amid the rise of China's cheap AI model DeepSeek, Sam Altman is facing backlash for his old remark about AI startups under ...